RossCarlKlingsbergMD

Pulmonology • New Orleans, LA

Critical Care Medicine, Cystic Fibrosis, Pleural Disease

Associate Professor, Medicine, Tulane University Sch of Med

Join to view full profile

Dr. Klingsberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Klingsberg's full profile

Already have an account?

Office
1415 Tulane Ave
New Orleans, LA 70112

Education & Training

Tulane UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2008
Tulane UniversityResidency, Internal Medicine, 2002 - 2005
University of Pennsylvania Health SystemInternship, Internal Medicine, 2002 - 2003
Tulane University School of MedicineClass of 2002

Certifications & Licensure

LA State Medical License 2003 - 2025
MS State Medical License 2019 - 2025
PA State Medical License 2002 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013

Clinical Trials

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF Start of enrollment: 2023 Apr 20
Recruiting
Roles: Contact

Publications & Presentations

PubMed

19 citations
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
Carsten Schwarz, Sivagurunathan Sutharsan, Ralph Epaud, Ross C. Klingsberg, Rainald Fischer
Journal of Cystic Fibrosis. 2021-03-01
CFTR modulator therapy improves cystic fibrosis-related diabetes. But how?
Christine M. Bojanowski, Sarah M. Wilson, Ross C. Klingsberg
Journal of Diabetes and Its Complications. 2021-02-25
26 citations
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR ...
Patrick A. Flume, Reta Fischer Biner, Damian G Downey, Cynthia A. Brown, Manu Jain
The Lancet. Respiratory Medicine. 2021-02-10

Press Mentions

New Cystic Fibrosis Medicine Changing Lives After Testing in New OrleansDecember 3rd, 2019